&nbsp;

Apr 2024

Drug

AFAtinib

Other Name(s): Giotrif®

Quick Link(s):

Apr 2024

Drug

iBRUtinib

Other Name(s): Imbruvica®

Quick Link(s):

Sep 2025

Drug

idelalisib

Other Name(s): Zydelig™

Quick Link(s):

Feb 2022

Drug

alectinib

Other Name(s): Alecensaro®

Quick Link(s):

Nov 2025

Regimen

AXIT

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

aXitinib - For second or third line treatment of advanced renal cell carcinoma, according to clinical criteria

Drugs Used:

aXitinib

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

AFAT

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

AFAtinib - For first-line monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria

Drugs Used:

AFAtinib

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

IBRU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

IDEL+RITU; IDEL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria

New Drug Funding Program

Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia

Drugs Used:

idelalisib,

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For the treatment of patients with relapsed or refractory Waldenstrӧm Macroglobulinemia, as monotherapy, based on criteria

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

ALEC

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to specific criteria

Drugs Used:

alectinib